Breaking News

Novartis to Acquire DTx Pharma for $500M Upfront

DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON) platform facilitates extra-hepatic delivery of siRNA therapeutics.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis has acquired DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON) platform, for $500 million upfront and additional payments of up to $500 million based on pre-specified milestones.   The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters